Published November 15, 2012 | Version v1
Journal article

Toward Semi-automated Assessment of Target Volume Delineation in Radiotherapy Trials: The SCOPE 1 Pretrial Test Case

  • 1. Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, Wales (United Kingdom)
  • 2. Department of Medical Physics, Velindre Cancer Centre, Cardiff, Wales (United Kingdom)
  • 3. Wales Cancer Trials Unit, School of Medicine, Cardiff University, Cardiff, Wales (United Kingdom)
  • 4. Department of Diagnostic Radiology, Velindre Cancer Centre, Cardiff, Wales (United Kingdom)
  • 5. Division of Cancer, School of Medicine, Cardiff University, Cardiff, Wales (United Kingdom)

Description

Purpose: To evaluate different conformity indices (CIs) for use in the analysis of outlining consistency within the pretrial quality assurance (Radiotherapy Trials Quality Assurance [RTTQA]) program of a multicenter chemoradiation trial of esophageal cancer and to make recommendations for their use in future trials. Methods and Materials: The National Cancer Research Institute SCOPE 1 trial is an ongoing Cancer Research UK-funded phase II/III randomized controlled trial of chemoradiation with capecitabine and cisplatin with or without cetuximab for esophageal cancer. The pretrial RTTQA program included a detailed radiotherapy protocol, an educational package, and a single mid-esophageal tumor test case that were sent to each investigator to outline. Investigator gross tumor volumes (GTVs) were received from 50 investigators in 34 UK centers, and CERR (Computational Environment for Radiotherapy Research) was used to perform an assessment of each investigator GTV against a predefined gold-standard GTV using different CIs. A new metric, the local conformity index (l-CI), that can localize areas of maximal discordance was developed. Results: The median Jaccard conformity index (JCI) was 0.69 (interquartile range, 0.62-0.70), with 14 of 50 investigators (28%) achieving a JCI of 0.7 or greater. The median geographical miss index was 0.09 (interquartile range, 0.06-0.16), and the mean discordance index was 0.27 (95% confidence interval, 0.25-0.30). The l-CI was highest in the middle section of the volume, where the tumor was bulky and more easily definable, and identified 4 slices where fewer than 20% of investigators achieved an l-CI of 0.7 or greater. Conclusions: The available CIs analyze different aspects of a gold standard–observer variation, with JCI being the most useful as a single metric. Additional information is provided by the l-CI and can focus the efforts of the RTTQA team in these areas, possibly leading to semi-automated outlining assessment.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2012.01.094

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2012.01.094;
PII
S0360-3016(12)00205-2;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
84
Journal Issue
4
Journal Page Range
p. 1037-1042
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
44104324
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ESOPHAGUS; METRICS; NEOPLASMS; QUALITY ASSURANCE; RADIOTHERAPY; RECOMMENDATIONS; STANDARDS
Descriptors DEC
BODY; DIGESTIVE SYSTEM; DISEASES; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.